# Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer

> **NCT00004236** · PHASE2 · UNKNOWN · sponsor: **University of Leicester**

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00004236
- **Lead sponsor:** University of Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004236, "Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*